There are significant concerns. Firstly, these malignancies have no screening intervention in place which would facilitate earlier diagnosis.
Secondly, the costs associated with diagnosis of these malignancies are potentially high. For instance, lung cancer requires complex imaging,
multidisciplinary assessment and invasive biopsies [87]. Thirdly, survival outcomes for lung, gastric, and hepatocellular carcinoma remain poor
even with maximal therapy.